Sunday - April 26, 2026

Category Archives: Marketing & Sales

Postherpetic Neuralgia Pipeline Set for Strategic Expansion by 2026 with Emerging Neuromodulatory Therapies and Clinical Advancements | DelveInsight

Postherpetic Neuralgia Pipeline Leading Postherpetic Neuralgia Companies include Ono Pharmaceutical Co. Ltd, Undaunted Bio, Shanghai SIMR Biotechnology Co., Ltd. and others. DelveInsight’s latest report, “Postherpetic Neuralgia Pipeline Insight, 2026,” offers comprehensive insights into 3+ companies and 3+ pipeline drugs within … Continue reading →

Wound Closure Devices Market to Reach USD 28.13 Billion by 2032, Growing at a 7.52% CAGR Driven by Rising Surgical Volumes and Advancements in Closure Technologies | DelveInsight

Wound Closure Devices Market Some of the key market players operating in the wound closure devices market include Medtronic, 3M, Johnson & Johnson Services, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Healthium Medtech, Meril Life Sciences … Continue reading →

Parkinson’s Disease Pipeline Accelerates with 200+ Therapies and 150+ Companies Driving Next-Gen Innovations | DelveInsight

Parkinson’s Disease Pipeline Key Parkinson’s Disease Companies are Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., Cerevance, IRLAB, Neuron23, Ventyx Biosciences, Lundbeck, Sanofi, Eli Lilly and Company, and others The Parkinson’s disease therapeutic landscape is undergoing a transformative shift as over … Continue reading →

Digital Wound Measurement Devices Market Shows Strong Growth Potential, Expected to Reach USD 565.83 Million by 2032, According to DelveInsight Digital Wound Measurement Devices Market

Digital Wound Measurement Devices Market Key Digital Wound Measurement Devices Companies are MolecuLight Inc., Wound Matrix Inc., Kent Imaging Inc., ARANZ Medical Limited, WoundVision LLC., Stryker, eKare Inc., Net, Perceptive Solutions, Inc., BioVisual Technologies LLC, Smith & Nephew, WoundRight Technologies, … Continue reading →

BPL-003 Sales Forecast to 2034 Signals Transformational Growth in Treatment-Resistant Depression Market Driven by Rapid-Acting Psychedelic Innovation | DelveInsight

BPL-003 Sales Forecast The global neuropsychiatry landscape is undergoing a paradigm shift, and at the center of this transformation is BPL-003, a next-generation intranasal psychedelic therapy poised to redefine the treatment approach for treatment-resistant depression (TRD) and other neuropsychiatric disorders. … Continue reading →

Myositis Pipeline Gains Strong Momentum with 45+ Therapies and 40+ Companies Advancing Next-Generation Autoimmune Treatments | DelveInsight

Myositis Clinical Trial Key Myositis companies such as Pfizer, Galapagos NV, Fate Therapeutics, Bristol-Myers Squibb, Gilead Sciences, and CRISPR Therapeutics are spearheading innovation with advanced biologics, small molecules, and cell-based therapies designed to improve treatment outcomes and redefine disease management … Continue reading →

Traumatic Brain Injury Pipeline Enters a New Era of Innovation with 20+ Companies and 22+ Therapies Targeting Neuroprotection and Regeneration | DelveInsight

Traumatic Brain Injury Clinical Trial Key Traumatic Brain Injury Companies are Oragenics, Inc., SHINKEI Therapeutics, Inc., AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, BioArctic, Tiziana Life Sciences, and others The Traumatic Brain Injury (TBI) therapeutic landscape is undergoing a transformative … Continue reading →

Phase 3 EMN24 IsKia Study: Quadruplet Isa-KRd Regimen Significantly Improves MRD Negativity in Newly Diagnosed Multiple Myeloma | DelveInsight’s Perspective on Treatment Paradigm Shift

Phase 3 EMN24 IsKia Study: Quadruplet Isa-KRd Regimen Significantly Improves MRD Negativity in Newly Diagnosed Multiple Myeloma The EMN24 IsKia results were based on rigorous NGS MRD testing in all patients who achieved at least a very good partial response. … Continue reading →

Breakthrough in Lupus Brain Fog Treatment: Vanderbilt Health and Evergreen Therapeutics Report Success in Phase 2 ClearMEMory Trial for EG501 | DelveInsight’s Perspective

Vanderbilt Health and Evergreen Therapeutics Report Success in Phase 2 ClearMEMory Trial for EG501 The Phase 2 ClearMEMory trial provided robust clinical evidence over a 12-week period. Patients receiving EG501 showed significant improvements in objectively measured cognitive performance scores compared … Continue reading →